title: Neonatal pancytopenia in a child, born after maternal exposure to natalizumab throughout pregnancy.
abstract: Natalizumab is a monoclonal antibody indicated for the treatment of patients with relapsing-remitting multiple sclerosis. Its use is prohibited during pregnancy. However, natalizumab exposures throughout the gestation period or during the third trimester, because of intense disease activity, are possible and begin to be reported. There are enough reassuring arguments against a teratogenicity, through pregnancy registries; but deleterious effects in the monitoring of newborn, are not well known. A disorder of hematopoiesis is possible with anemia, thrombocytopenia or pancytopenia, as discussed by the author through an observation. These hematological disorders seem to be asymptomatic; they resolve spontaneously and require a simple biological and clinical monitoring of the newborn.
authors.affiliation: Service de neurologie, HIA Desgenettes, 108, boulevard Pinel, 69275 Lyon cedex 03, France. Electronic address: lguilloton0607@gmail.com.
authors.forename: L
authors.initials: L
authors.lastname: Guilloton
authors.affiliation: Service de neurologie, HIA Desgenettes, 108, boulevard Pinel, 69275 Lyon cedex 03, France.
authors.forename: A
authors.initials: A
authors.lastname: Pegat
authors.affiliation: Service de neurologie, HIA Desgenettes, 108, boulevard Pinel, 69275 Lyon cedex 03, France.
authors.forename: J
authors.initials: J
authors.lastname: Defrance
authors.affiliation: Service de neurologie, HIA Desgenettes, 108, boulevard Pinel, 69275 Lyon cedex 03, France.
authors.forename: L
authors.initials: L
authors.lastname: Quesnel
authors.affiliation: Cabinet de gynécologie, 12, chemin de la Croix-Pivort, 69110 Sainte-Foy-les-Lyon, France.
authors.forename: G
authors.initials: G
authors.lastname: Barral
authors.affiliation: Service de neurologie, HIA Desgenettes, 108, boulevard Pinel, 69275 Lyon cedex 03, France.
authors.forename: A
authors.initials: A
authors.lastname: Drouet
mesh_terms: D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab / Q000009:adverse effects*; D010198:Pancytopenia / Q000139:chemically induced*; D011247:Pregnancy; D055815:Young Adult
chemical_list: D007155:Immunologic Factors; D000069442:Natalizumab
keywords: Grossesse; Multiple sclerosis; Natalizumab; Pregnancy; Sclérose en plaque